We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

66 hedge funds and large institutions have $130M invested in Palvella Therapeutics in 2017 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

340% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 5

70% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 10

35% more funds holding

Funds holding: 49 → 66 (+17)

14% more capital invested

Capital invested by funds: $114M → $130M (+$16.3M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.02% less ownership

Funds ownership: 0.65% → 0.64% (-0.02%)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $95K

Holders
66
Holders Change
+17
Holders Change %
+34.69%
% of All Funds
1.65%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
22
Increased
17
Reduced
10
Closed
5
Calls
–
Puts
$95K
Net Calls
-$95K
Net Calls Change
-$95K

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$1.5M
2
BIM
Bogle Investment Management
Massachusetts
+$1.15M
3
Millennium Management
Millennium Management
New York
+$1.1M
4
Cerity Partners
Cerity Partners
New York
+$856K
5
JP Morgan Chase
JP Morgan Chase
New York
+$545K

Top Sellers

1
LOAMU
Lombard Odier Asset Management (USA)
New York
-$3.66M
2
BI
BVF Inc
California
-$2.7M
3
OFM
Omega Fund Management
Massachusetts
-$871K
4
IBT
International Biotechnology Trust
United Kingdom
-$712K
5
SFM
Sphera Funds Management
Israel
-$534K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$41.8M – – –
BI
2
BVF Inc
California
$17.2M -$2.7M -6,317 -14%
TCM
3
Tekla Capital Management
Massachusetts
$16.3M – – –
BlackRock
4
BlackRock
New York
$8.8M +$224K +524 +3%
OFM
5
Omega Fund Management
Massachusetts
$6.93M -$871K -2,040 -12%
SFM
6
Sphera Funds Management
Israel
$5.76M -$534K -1,250 -9%
SSA
7
Schonfeld Strategic Advisors
New York
$4.18M -$453K -1,062 -10%
LOAMU
8
Lombard Odier Asset Management (USA)
New York
$3.88M -$3.66M -8,580 -50%
State Street
9
State Street
Massachusetts
$2.98M +$253K +592 +10%
Millennium Management
10
Millennium Management
New York
$2.55M +$1.1M +2,585 +88%
Renaissance Technologies
11
Renaissance Technologies
New York
$2.29M +$1.5M +3,515 +243%
Northern Trust
12
Northern Trust
Illinois
$1.85M – – –
Morgan Stanley
13
Morgan Stanley
New York
$1.28M -$215K -504 -15%
TCIM
14
TIAA CREF Investment Management
New York
$1.25M +$477K +1,118 +70%
BIM
15
Bogle Investment Management
Massachusetts
$1.24M +$1.15M +2,687 New
EI
16
EAM Investors
California
$953K – – –
Cerity Partners
17
Cerity Partners
New York
$923K +$856K +2,004 New
Vanguard Group
18
Vanguard Group
Pennsylvania
$606K +$5.12K +12 +0.9%
JP Morgan Chase
19
JP Morgan Chase
New York
$600K +$545K +1,276 New
Acadian Asset Management
20
Acadian Asset Management
Massachusetts
$587K +$373K +873 +218%
Goldman Sachs
21
Goldman Sachs
New York
$575K +$469K +1,099 +738%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$574K +$106K +248 +25%
FQ
23
First Quadrant
California
$473K +$438K +1,026 New
Wellington Management Group
24
Wellington Management Group
Massachusetts
$447K +$415K +971 New
Bank of New York Mellon
25
Bank of New York Mellon
New York
$436K +$25.2K +59 +7%
1
2 3

PVLA Hedge Fund Activity: Q3 2017 in Review

66 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2017, worth a combined $130M — up 14% from $114M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new PVLA positions and 5 closed out — a net gain of 17 holders — while 17 added to existing stakes and 10 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $1.5M. The largest seller was Lombard Odier Asset Management (USA), cutting an estimated $3.66M.

  • 66 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2017, up from 49 in Q2 2017.
  • Funds reported $130M of Palvella Therapeutics stock for Q3 2017, up 14% quarter-over-quarter.
  • 22 funds opened new Palvella Therapeutics positions in Q3 2017 and 5 closed out, a net change of +17 holders.
  • The largest Palvella Therapeutics buyer in Q3 2017 was Renaissance Technologies, an estimated $1.5M added.
  • The largest Palvella Therapeutics seller in Q3 2017 was Lombard Odier Asset Management (USA), an estimated $3.66M sold.

Based on aggregated 13F filings for Q3 2017.